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Background: Etorphine, a potent opioid agonist, causes pulmonary hypertension and respiratory depression.
Whether etorphine-induced pulmonary hypertension negatively influences pulmonary gas exchange and
exacerbates the effects of ventilator depression and the resultant hypoxemia is unknown. To determine if these
effects occurred we instrumented twelve goats with peripheral and pulmonary arterial catheters to measure
systemic and pulmonary pressures before and after etorphine administration. Concurrent cardiopulmonary and
arterial blood gas variables were also measured.
Results: Etorphine induced hypoventilation (55% reduction to 7.6 ± 2.7 L.min−1, F(11,44) = 15.2 P < 0.0001), hypoxia
(<45 mmHg, F(11,44) = 8.6 P < 0.0001), hypercapnia (>40 mmHg, F(11,44) = 5.6 P < 0.0001) and pulmonary hypertension
(mean 23 ± 6 mmHg, F(11,44) = 8.2 P < 0.0001). Within 6 min of etorphine administration hypoxia was twice
(F(11,22) = 3.0 P < 0.05) as poor than that expected from etorphine-induced hypoventilation alone. This disparity
appeared to result from a decrease in the movement of oxygen (gas exchange) across the alveoli membrane,
as revealed by an increase in the P(A-a)O2 gradient (F(11,44) = 7.9 P < 0.0001). The P(A-a)O2 gradient was not
correlated with global changes in the ventilation perfusion ratio (P = 0.28) but was correlated positively with
the mean pulmonary artery pressure (P = 0.017, r2 = 0.97), indicating that pulmonary pressure played a significant
role in altering pulmonary gas exchange.
Conclusion: Attempts to alleviate etorphine-induced hypoxia therefore should focus not only on reversing the
opioid-induced respiratory depression, but also on improving gas exchange by preventing etorphine-induced
pulmonary hypertension.
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Although opioids are effective in reducing pain and indu-
cing anaesthesia, sedation or chemical immobilization,
their use is not without complications or harmful side-
effects. Of these side-effects, respiratory compromise is
the most detrimental and well known [1-3]. Patients given
opioids may develop hypercapnia, respiratory acidosis and
hypoxia [4,5]. The respiratory compromise usually is
attributed to respiratory depression, characterised by slow-
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unless otherwise stated.responses to hypercapnia, caused by the depressive effects
of the opioids on the respiratory network and other neu-
rons in the brain-stem [6,7]. Opioids also depress hypoxic
and hypercapnic ventilator responses by acting on periph-
eral chemoreceptors [6,8].
We have reason to believe, though, that respiratory de-
pression is not the sole cause of opioid-induced hypoxia.
Serotonergics drugs improve respiratory rhythmogenesis
through their effects on respiratory neurons [3,5,8]. How-
ever, when we used serotonergic drugs, acting on 5-HT1A
and 5-HT4 receptors, to reverse etorphine-induced re-
spiratory compromise, we found that their hypoxia-
relieving effects were not related solely to their actions on
respiratory neurons, but also their effects on pulmonary
gas exchange [4,9]. We postulated that the improvementsThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of these serotonergic drugs, which countered etorphine’s
vasoconstrictor effects in the pulmonary circulation [7].
We now have tested that postulate. We determined how
etorphine, a potent opioid agonist widely used in chemical
immobilization of wildlife [2], altered pulmonary arterial
blood pressure and gas exchange, and established how
much these effects contributed to etorphine-induced
hypoxia. We measured blood gases, pulmonary pres-
sures and other cardiorespiratory variables before and
after etorphine administration in goats.
Methods
Twelve adult female mix breed goats (Capra hircus),
weighing 33 ± 5 kg (mean ± SD), were used in this mech-
anistic study. They were housed together in temperature-
controlled indoor pens (~22°C) in Johannesburg, at an
altitude of 1753 m, on a 12 hour light/dark cycle (lights on
6:00). The goats were reared at this altitude and therefore
adapted to lower inspired partial pressures of oxygen than
at sea-level. They had water ad libitum and were fed on
hay and sheep concentrate pellets. For six weeks before
the start of data collection the goats were habituated to
being restrained in sternal recumbency on a work table
with a face mask over their muzzle, for a 5 min period
every other day. The procedures were approved by the
University of the Witwatersrand’s Animal Ethics Screening
Committee (clearance number 2008/49/04).
Goats were weighed 48 hours before, and starved for
24 hours before etorphine administration to reduce the
risk of bloating and of regurgitation of ingesta. On the day
of etorphine administration, each goat was restrained in
sternal recumbency and its ears and left lateral neck area
was shaved and swabbed with 5% chlorhexidine gluconate
(Hibitane, Astra Zeneca, Johannesburg, South Africa) in
100% ethanol. A 22 gauge intravenous catheter (Introcan,
B/Braun, Melsungen, Germany) was placed in one of
the auricular arteries and connected via a fluid-filled arter-
ial line to a pre-calibrated Deltran II pressure transducer
(DPT-200, Utah Medical Products, Midvale, U.S.A.).
Local anaesthetic (2 ml lignocaine, Bayer, South Africa)
was injected subcutaneously around the left jugular vein
before an 2.8 mm (outside diameter) introducer sheath
(1350BF85, Edwards Life Sciences, Irene, South Africa)
was inserted into the vein. A fluid-filled Swan-Ganz
Catheter (Continuous Cardiac Output Thermodilution
Catheter, 139HF75P, Edwards Life Sciences, Irene, South
Africa), which was connected to another Deltran II pres-
sure transducer, was inserted through this sheath and
advanced through the vein and right heart. Under the
guidance of the real-time pressure trace, the tip of the
catheter was positioned in the pulmonary artery such that
when the balloon of the catheter was inflated it “wedged”
the artery. This placement enabled the measurement ofboth pulmonary artery (averaged over 40s every minute)
and pulmonary artery wedge (averaged over 10s every sec-
ond minute) pressures. Through a three-way stopcock, a
separate side-port of the Swan-Ganz catheter was con-
nected to the pressure transducer to measure central
venous pressure (averaged over 10s every other second
minute). To standardise pressure readings the pressure
transducers were placed at the level of the scapulohumeral
joint (level of the heart base). The Swan-Ganz transducers
were connected via blood pressure amplifiers (FE117,
ADIntruments, Castle Hill, Australia) to a PowerLab Exer-
cise Physiology System (ML870B80, ADIntruments, Castle
Hill, Australia), which captured and displayed real-time
data through LabChart software (Chart 5, ADIntruments,
Castle Hill, Australia). The Swan-Ganz catheter also was
connected to a Vigilance Monitor (Edwards Life Sciences,
Irene, South Africa), which continuously measured pul-
monary artery temperature and cardiac output based on
thermodilution principles. Pulmonary artery temperature
was used as the body temperature needed to calculate
water vapour pressure in alveolar air and to allow for
temperature-corrected blood gas measurements.
A clear canine anaesthetic face mask (J-298C, Jorgensen
Laboratories, Loveland, USA) was placed over the muzzle
of the goat and positioned so as to limit dead space. A gas-
ket made from a latex glove formed a tight seal between
the goat’s muzzle and the face mask. The face mask was
connected to a two-way valve which directed all the ex-
pired air into the PowerLab Exercise Physiology System,
via a respiratory flow head (MLT1000L) linked to a spir-
ometer (ML140) and a gas mixing chamber (MLA245), in
which expired gas temperature was measured by a ther-
mistor pod (ML309). The data from these modules were
collected via the PowerLab 8/30 amplifier (ML870) and
integrated with the Metabolic Module software to meas-
ure (at BTPS - body temperature and pressure saturated)
minute ventilation (L.min−1) and respiratory rate. Prior to
each set of measurements the spirometer was calibrated
using a 3 L calibration syringe.
Data were recorded from 4 min before the injection of
etorphine hydrochloride (Captivon, Wildlife Pharmaceuti-
cals, Whiteriver, South Africa) until 15 min after the injec-
tion. Etorphine was injected intramuscularly into the
gluteus muscles using a 20G hypodermic needle at a dose
of 0.1 mg.kg−1 (the drug was diluted in injectable water to
standardise the volume injected to 1 ml) a dose shown in
pilot studies to induce motionless immobilization for the
15 min of data recording and to have no long-term seque-
lae. Once immobile, the goats were positioned by a hand-
ler holding the horns so that the neck was aligned with
the spinal column and the head was elevated above the
thorax with the nose pointing downwards. This position-
ing allowed for unobstructed eructation of ruminal gas
and an open upper airway. A 0.5 ml auricular arterial
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14 min after etorphine injection (these time intervals were
selected a priori); the catheter was flushed with 2 ml hepa-
rinized saline (5 iu.ml−1, Heparin, Intramed, Johannesburg,
South Africa) after each sample. Directly after each sample
was drawn, the arterial partial pressure of oxygen (PaO2),
carbon dioxide (PaCO2) and pH were measured on a pre-
calibrated blood gas analyzer with pre-calibrated blood gas
cassettes (Roche OPTI CCA Analyzer + OPTI cassette B,
Kat Medical, Johannesburg, South Africa); data were re-
ported at 37°C.
At the end of the recording period, all instruments were
removed and the goats were returned to their pens, where
the action of etorphine was antagonised by 2 mg.kg−1 nal-
trexone hydrochloride (Trexinol, Wildlife Pharmaceuticals,
White River, South Africa) injected intramuscularly.
All measurements were made indoors, between 2 hours
and 10 hours after lights-on, at an ambient dry-bulb
temperature between 20°C and 22°C and relative humid-
ity between 21% and 24%. Barometric pressures were
measured to an accuracy of 0.1 mmHg, by the on-board
barometer of the blood gas analyzer, which had been cal-
ibrated against a Fortin mercury barometer (On, F.D &
Co Ltd, United Kingdom). Barometric pressure ranged
from 628 mmHg to 634 mmHg. At that barometric
pressure, the partial pressure of inspired oxygen was
about 133 mmHg.
We used GraphPad Prism version 6 for Windows
(GraphPad Software, San Diego, USA) for statistical ana-
lyses. All results are reported as mean ± SD, and a P < 0.05
was considered statistically significant. Partial pressure
of alveolar oxygen (PAO2) was determined by using the
Alveolar Gas Equation (FiO2 (Pb – PH2O) – PaCO2/RQ)
where FiO2 is the fractional inspired oxygen (0.209), Pb
the measured barometric pressure (mmHg) and PH2O the
water vapour pressure of saturated air in the alveoli.
PH2O (mmHg) was calculated as 4.58 e{(17.27 × Tb)/
(237.3 + Tb)} [10], where Tb is the body temperature. We
assumed that the partial pressure of CO2 in the alveoli
was equal to the arterial partial pressure of CO2 (PaCO2)
and used a RQ (respiratory quotient) value of 1, the norm
in conscious healthy goats [11]. The alveolar-arterial oxy-
gen partial pressure gradient P(A-a)O2 was calculated as
PAO2 - PaO2. Expected-PaO2, a theoretical value of arter-
ial partial pressure of oxygen that would be expected if the
PaO2 after etorphine administration was determined only
by PAO2, which would decrease when ventilation de-
creased, was calculated by assuming that P(A-a)O2
remained at the value attained immediately before etor-
phine administration. Pulmonary vascular resistance was
calculated by dividing the difference between the pulmon-
ary artery and wedge pressure by the cardiac output. Glo-
bal ventilation perfusion ratios were calculated by dividing
ventilation by cardiac output.A repeated measures two-way ANOVA followed by a
Šídák’s post-hoc test for multiple comparisons was used
to test for differences between measured PaO2 and ex-
pected PaO2 across time following etorphine administra-
tion. A repeated measures one-way ANOVA followed by
Dunnett’s post-hoc test for multiple comparisons with a
control was used to test for differences between values
2 min before etorphine administration and those after
etorphine administration, for respiration rate, ventila-
tion, heart rate, cardiac output, ventilation perfusion
ratio, PaCO2, P(A-a)O2, systemic arterial pressures, pul-
monary arterial pressures, pulmonary arterial wedge
pressure and pulmonary vascular resistance at each time
point that blood gases were measured (2, 6, 10 and
14 min) after etorphine administration. Pearson’s corre-
lations and linear regressions were used to test for linear
relationships between mean (averaged over 12 animals)
P(A-a)O2, PaO2, mean pulmonary artery pressure and
other cardiorespiratory variables. Although the correla-
tions were similar when pre-etorphine data were in-
cluded, only post-etorphine administration data were
included to avoid cloud regressions.
Results
Effects of etorphine on immobilization and
cardiorespiratory function
Administration of etorphine induced immobilization
within 2–3 min, following which the goats remained
motionless and unresponsive to moderate sound (talk-
ing) and physical stimuli (blood sampling and the palpe-
bral reflex test) for the 15 min of measurements. Before
etorphine administration (−2 min) the goats had a
respiratory rate of 35 ± 10 breaths.min−1 and minute
ventilation was 13.7 ± 3.3 L.min−1. Following etorphine
administration, both respiratory rate (F(11,44) = 11.9
P < 0.0001) and ventilation (F(11,44) = 15.2 P < 0.0001)
decreased significantly. Within 2 min of etorphine ad-
ministration the respiratory rate decreased to 16 ± 7
breaths.min−1 and minute ventilation to 7.6 ± 2.7 L.min−1
(Figure 1A), levels close to which they remained through-
out the immobilization. Heart rate, which was 108 ± 25
beats.min−1 before etorphine administration, did not
change significantly following etorphine administration
(F(11,44) = 4.1 P = 0.30). Cardiac output (3.9 ± 0.7 L.min
−1
before etorphine administration) did not change immedi-
ately after etorphine administration, but decreased grad-
ually from 3.8 ± 0.5 L.min−1 at 6 min to 3.4 ± 0.5 L.min−1
at the end of the immobilization (14 min), resulting in
cardiac output being significantly lower overall, follow-
ing etorphine administration (F(11,44) = 18.9 P = 0.01,
Figure 1B). Global ventilation perfusion ratio across the
lung, which was 3.5 ± 0.9 before etorphine administra-
tion, decreased to 2.0 ± 0.9 at 2 min, and remained low
(2.1 ± 0.8) throughout the immobilization, so that,
Figure 1 Effects of etorphine (0.1 mg.kg−1) injected
intramuscularly (time = 0) on ventilation (A), cardiac output (B)
and global ventilation perfusion ratio (C) in goats (mean ± SD,
n = 12). # P < 0.05 pre-etorphine vs. post-etorphine (repeated
measures one-way ANOVA with post hoc Dunnett’s test) at time
2, 6, 10 and 14 min.
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phine administration (F(11,44) = 32.3 P < 0.0001, Figure 1C).
Effects of etorphine on blood gases
Figure 2A shows the effect of etorphine on measured ar-
terial partial pressure of oxygen (PaO2). PaO2 was 65 ±
6 mmHg before etorphine administration (−2 min) anddecreased to below 45 mmHg at 2 and 6 min after etor-
phine administration (F(11,44) = 8.6 P < 0.0001), before
gradually increasing again. The arterial partial pressure
of carbon dioxide (PaCO2) before etorphine administra-
tion was 31 ± 3 mmHg; after etorphine administration it
increased (F(11,44) = 5.6 P < 0.0001) to above 40 mmHg
(9–12 mmHg increase) from 6 min to the end of the
immobilization (Figure 2B). The alveolar arterial oxygen
partial pressure difference (P(A-a)O2) was 25 ± 5 mmHg
before etorphine administration and increased after etor-
phine administration (F(11,44) = 7.9 P < 0.0001), although
it had returned to the pre-etorphine difference within
10 min after etorphine administration (Figure 2C).
Following etorphine administration, the calculated ar-
terial partial pressure of oxygen that would be expected
if the partial pressure of oxygen was influenced only by a
decrease in ventilation, that is assuming that P(A-a)O2
did not change, was lower than before etorphine admin-
istration (F(11,44) = 22.7 P < 0.0001), and was greater than
measured PaO2 (F(11,22) = 3.0 P < 0.05), though expected
and measured values were the same after 10 min after
etorphine administration (Figure 2A).
Effects of etorphine on the systemic and pulmonary
vasculature
After etorphine administration, the systemic arterial pres-
sures decreased (systolic F(11,44) = 6.8 P < 0.0001; mean
F(11,44) = 8.2 P < 0.0001; diastolic F(11,44) = 8.6 P < 0.0001),
with decreases significant after 6 min (Figure 3A). Before
the administration of etorphine (−2 min), pulmonary
artery systolic pressure was 21 ± 5 mmHg, mean was 13 ±
4 mmHg and diastolic was 7 ± 4 mmHg (Figure 3B). Pul-
monary artery pressures increased after etorphine admin-
istration (systolic F(11,44) = 6.8 P < 0.0001, mean F(11,44) =
8.2 P < 0.0001, diastolic F(11,44) = 8.6 P < 0.0001), with
systolic, mean and diastolic pressures all being signifi-
cantly higher within 2 min after etorphine administration
but returning to pre-etorphine values by the end of the
immobilization. Pulmonary vascular resistance (F(11,44) =
2.6 P = 0.01) and pulmonary artery wedge pressure
(F(11,44) = 11.88 P < 0.0001) were increased after etorphine
administration from 2.9 ± 1.1 mmHg.min.L−1 and from
4.1 ± 2.9 mmHg respectively (Figure 3C), but only because
values 3 min after etorphine administration were elevated
significantly.
Factors influencing arterial partial pressure of oxygen
Although etorphine administration resulted in reduced
ventilation and PaO2, after etorphine administration
there was no significant linear relationship between ven-
tilation and the PaO2 (Figure 4A, P = 0.16, r
2 = 0.70).
In support of the poor influence of ventilation on
PaO2 after etorphine administration, we found that
the arterial partial pressure of carbon dioxide (PaCO2,
Figure 2 Effects of etorphine (0.1 mg.kg−1) injected
intramuscularly (time = 0) on measured arterial partial pressure
of oxygen (PaO2, solid symbols) and the theoretical value of
arterial partial pressure of oxygen calculated assuming that
alveolar-arterial oxygen partial pressure gradient P(A-a)O2
remained constant (Expected-PaO2, open symbols) (A), arterial
partial pressure of carbon dioxide (B) and alveolar-arterial
oxygen partial pressure gradient P(A-a)O2 (C) in goats (mean ±
SD, n = 12). # P < 0.05 pre-etorphine vs. post-etorphine (repeated
measures two-way ANOVA with post hoc Sidak’s multiple comparison
test (A) and repeated measures one-way ANOVA with post hoc
Dunnett’s test (B&C)), * P < 0.05 PaO2 vs. expected-PaO2 (repeated
measures two-way ANOVA with post hoc Sidak’s multiple
comparison test (A)) at time 2, 6, 10 and 14 min.
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pressure of oxygen (PAO2, P = 0.99, r
2 < 0.01), both vari-
ables associated with the magnitude of ventilation, were
not correlated with PaO2. Global pulmonary perfusion,
measured as cardiac output (P = 0.60, r2 = 0.88), also was
not correlated to PaO2. However, the relationship be-
tween global ventilation and perfusion (the ventilation
perfusion ratio) after etorphine administration was cor-
related with the PaO2 (P = 0.04, r
2 = 0.92, Figure 4B).
Therefore, the changes in the PaO2 appeared to be at-
tributed mainly to intrapulmonary ventilation-perfusion
mismatching rather than the pump action of breathing
i.e. ventilation. That the main problem lay with altered
oxygen movement across the alveoli membrane, not oxy-
gen delivery, was confirmed by the large increase in the
alveolar-arterial oxygen partial pressure gradient (P(A-a)
O2) soon after etorphine administration (Figure 2C).
After etorphine administration, P(A-a)O2 was linearly cor-
related with mean pulmonary artery pressure (Figure 4C,
P = 0.017, r2 = 0.97) and pulmonary vascular resistance
(Figure 4D, P = 0.023, r2 = 0.95), but not significantly cor-
related with global ventilation (P = 0.59, r2 = 0.17), cardiac
output (P = 0.17, r2 = 0.69), global ventilation perfusion
ratio (P = 0.28, r2 = 0.52) or pressures in the left atrium as
indicated by pulmonary artery wedge pressure (P = 0.07,
r2 = 0.87).
Pulmonary artery pressure after etorphine administra-
tion was correlated with pulmonary vascular resistance
(P = 0.04, r2 = 0.52), pulmonary artery wedge pressure
(Figure 4E, P = 0.0004, r2 = 0.77) and cardiac output
(Figure 4F, P = 0.003, r2 = 0.47), but not PAO2 (P = 0.61,
r2 = 0.15). PAO2 was also not correlated with pulmonary
vascular resistance (P = 0.28, r2 = 0.51).
Discussion
Intramuscular administration of 0.1 mg.kg−1 etorphine, a
highly-potent opioid receptor agonist, induced rapid
chemical immobilization and decreased the partial pres-
sure of oxygen in arterial blood (Figure 2A). One cause
of this exacerbated hypoxia could be hypoventilation,
which opioid agonists are well known to induce (4–6).
Our goats did develop hypoventilation (Figure 1A) with
the expected concomitant hypercapnia (Figure 2B), but
hypoventilation was not the only, nor even the primary,
cause of the hypoxia. In the first six minutes after etor-
phine administration, when the hypoxia was most severe,
the arterial partial pressure of oxygen was about half that
which would have resulted from hypoventilation alone
(Figure 2A). So not only was oxygen delivery to the alveoli
compromised but so to was exchange of oxygen between
alveoli and arterial blood. The alveolar-arterial oxygen par-
tial pressure gradient (P(A-a)O2) increased precipitously
within 2 min of etorphine administration (Figure 2C). We
identified one direct cause of the compromise of alveolar-
Figure 3 Effects of etorphine (0.1 mg.kg−1) injected intramuscularly (time = 0) on systemic artery (A), pulmonary artery (B) and
pulmonary artery wedge pressures and pulmonary vascular resistance (C) in goats (mean ± SD, n = 12). # P < 0.05 pre-etorphine vs
post-etorphine (one-way ANOVA with post hoc Dunnett’s test) at time 2, 6, 10 and 14 min.
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ministration pulmonary vascular resistance also increased
precipitously (Figure 3C) and pulmonary hypertension de-
veloped (Figure 3B). The alveolar-arterial oxygen partial
pressure gradient (P(A-a)O2) after etorphine administra-
tion was correlated strongly with mean pulmonary artery
pressure (Figure 4C) indicating that the pulmonary hyper-
tension likely played a major role in hindering oxygenmovement (gas exchange) across the alveoli membrane. It
is reasonable to speculate that hypoxia could have been
brought about by hydrostatic fluid shifts causing oedema
of the interstitium, and possibly also the alveoli, so in-
creasing diffusion distance and obstructing oxygen trans-
fer into the blood.
Pulmonary hypertension can develop without pulmon-
ary vascular resistance increasing, for example if global
Figure 4 Mean arterial partial pressure of oxygen (PaO2) vs. mean ventilation (A, r2 = 0.7, P = 0.16), mean arterial partial pressure of
oxygen (PaO2) vs. mean global ventilation perfusion ratio (B, r2 = 0.92, P = 0.04, y = 21x + 3.6), mean alveolar-arterial oxygen partial
pressure gradient vs. mean of mean pulmonary artery pressure (C, r2 = 0.97, P = 0.017, y = 1.3x + 8.9), mean alveolar-arterial oxygen
partial pressure gradient vs. mean pulmonary vascular resistance (D, r2 = 0.95, P = 0.024, y = 11.9x – 6.5), mean pulmonary artery
pressure vs. mean pulmonary artery wedge pressure (E, r2 = 0.77, P = 0.004, y = 1.5x + 8.4), mean pulmonary artery pressure vs. cardiac
output (F, r2 = 0.47, P = 0.003, y = 9.5x – 17.2). Data were averaged for 12 goats and r is Pearson’s correlation coefficient.
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output, and therefore global pulmonary blood flow, had
not changed at the time at which the hypoxia was most
severe (Figure 1B). Although cardiac output was corre-
lated with pulmonary artery pressures (Figure 4F) this
relationship was poor and resulted mainly from the de-
crease in cardiac output and pulmonary artery pressures
towards the end of the immobilization. Another possible
cause of pulmonary hypertension is increase in left atrial
pressure. In our goats, pulmonary artery wedge pressure,
the surrogate for left atrial pressure, did increase follow-
ing etorphine administration (Figure 3C) and mean
pulmonary artery pressures did correlate positively with
pulmonary artery wedge pressures (Figure 4E), so in-
creases in pressure in the left atrium could have contrib-
uted to the pulmonary hypertension. However, changesin pulmonary artery wedge pressure could not have en-
tirely accounted for the almost two-fold increase in the
mean pulmonary artery pressure, and we believe that the
main contributor to the pulmonary hypertension must
have been the increased pulmonary vascular resistance.
The most-likely cause of the increased pulmonary
vascular resistance was pulmonary vasoconstriction. Pul-
monary vasoconstriction following etorphine administra-
tion may result from activation of the sympathetic
nervous system by etorphine [12], from the indirect ef-
fects of the hypoxia and hypercapnia [13] induced by
etorphine [14,15], or by other unknown actions of etor-
phine on the pulmonary vasculature. However, general-
ised sympathetic activation appeared not to occur in
our goats, as heart rate and systemic artery pressure did
not increase. Hypoxic pulmonary vasoconstriction [16],
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have contributed to the increased pulmonary artery pres-
sures, but it did not appear to be the predominant factor,
as changes in ventilation, as indicated by the partial pres-
sures of alveolar oxygen and arterial carbon dioxide, were
not correlated with the changes in pulmonary artery pres-
sures and the partial pressure of alveolar oxygen was not
correlated to pulmonary vascular resistance. The precise
mechanisms underlying etorphine-induced and other pos-
sible opioid-induced pulmonary vasoconstriction still need
to be elucidated.
If, indeed, etorphine administration induced pulmon-
ary vasoconstriction, there is another possible contribu-
tor to the impaired oxygen transfer between alveoli and
arterial blood, in addition to the impairment resulting
from pulmonary hypertension. Less oxygen may have
entered the arterial blood because there was less time
for gas exchange to occur [16,17] after etorphine admin-
istration. Because pulmonary blood flow (cardiac output,
Figure 1B) had not changed at the time at which pul-
monary vascular resistance (Figure 3C) and, we presume,
vasoconstriction were greatest, the speed of red cells tra-
versing the narrowed pulmonary vessels would have
increased. If arterial blood traversed the pulmonary ca-
pillary in less than 0.25 seconds, oxygen would not have
enough time to diffuse and equilibrate in the blood [16].
Although we believe that pulmonary vasoconstriction
and the resultant pulmonary hypertension were the main
factors impairing oxygen exchange between alveoli and
arterial blood, other factors may have been operating
too. Following etorphine administration, there was a
strong relationship between the PaO2 and the global
ventilation perfusion ratio (Figure 4B), but there was no
significant relationship between global ventilation perfu-
sion ratio and P(A-a)O2. Additional ways in which the
relationship between ventilation and blood oxygenation
could be impaired include shunting, but we were unable
to measure shunt fractions, or regional ventilation perfu-
sion relationships in the lungs.
Etorphine not only had cardiovascular effects on the
pulmonary circulation. Although we did not measure
right atrial pressure, and therefore could not calculate
systemic vascular resistance, we do know that, after etor-
phine administration, mean systemic arterial pressure
dropped at a time at which cardiac output had not chan-
ged. The likely explanation was that etorphine’s effects
induced systemic vasodilation, in contrast to the pul-
monary vasoconstriction that it induced. The modest
increase in pulmonary artery wedge pressure, implying
a modest increase in left atrial pressure, and the eventual
decline in cardiac output, presumably indicate an effect
of etorphine on the heart itself. We note, too, that there
was no immediate change in heart rate following etor-
phine administration in spite of changes in systemicarterial pressure, possibly reflecting etorphine-induced
impairment of the baroreceptor reflex.
We are not the first to report that etorphine, and other
potent opioids like carfentanil, cause pulmonary hyperten-
sion [15], a response that has been implicated in the devel-
opment of severe pulmonary oedema in animals [18,19].
Pulmonary hypertension and oedema also occur in humans
who abuse heroin, morphine, opium and methadone [20].
As far as we are aware, the mechanisms by which acute
opioid administration influences pulmonary oxygen ex-
change have not been explored previously. The effects of
pulmonary hypertension on gas exchange have been studied
in chronic pulmonary disease [21] and heart failure [22,23],
where pulmonary hypertension can either have a protective
or pathophysiological effects. Not all studies on the effects
of opioids on the pulmonary vasculature are congruent; in
the pulmonary vasculature of cats, Hakim et al. [20] found
that morphine had vasoconstrictor effects whereas Kaye
et al. [24] found vasodilator effects. The reasons for this dis-
parity are not clear, but, intriguingly, in both studies the
vasoactive effects described were antagonised by naloxone
and chlorpheniramine or diphenhydramine, indicating that
these effects were mediated or modulated by both opioid-
receptor and histamine-receptor sensitive pathways [20,24].
In our study, acute etorphine administration led to pul-
monary hypertension and systemic hypotension. The
increased pulmonary artery pressures had a significant
and important clinical impact on our goats. Traditionally
hypoxia following etorphine administration has been
attributed to its depressive effects on respiratory rhythmo-
genesis and control (i.e. opioid-induced respiratory depres-
sion). However, we have shown, for the first time, that the
initial and most severe hypoxia caused by etorphine results
mainly from the effects of pulmonary hypertension on al-
veoli gas exchange. Although these effects were temporary
in our goats, their magnitude and timing is clinically sig-
nificant as the first ten minutes after opioid administration
is the time when the most lethal complications from etor-
phine immobilization can occur [4]. Whether similar pul-
monary hypertension, causing a decrease in pulmonary gas
exchange, results from administration of other opioids still
needs to be investigated, particularly for those opioids used
as immobilizing and anaesthetic induction agents.
Conclusion
Because etorphine-induced pulmonary hypertension played
such an important role in the development and severity of
hypoxia, methods of alleviating respiratory derangements
from etorphine, and possibly other opioid agonists, should
focus not only on reversing the opioid-induced central
respiratory depression, but also on improving oxygen
movement across the alveoli membrane, by preventing
pulmonary vasoconstriction particular in areas of the lungs
that are well ventilated.
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